Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01586325
Other study ID # CR100718
Secondary ID 47910382HPC1003
Status Terminated
Phase Phase 1
First received
Last updated
Start date May 25, 2012
Est. completion date April 21, 2014

Study information

Verified date March 2019
Source Janssen R&D Ireland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (how a drug is absorbed and distributed in the body), and intrinsic antiviral activity of JNJ-47910382 after 5 consecutive days of administration in chronic, hepatitis C virus (HCV)-genotype-1-infected patients at different doses and dose regimens.


Description:

This is a double-blind (neither physician nor patient knows the name of the assigned drug), randomized (patients are assigned by chance to treatment groups) placebo-controlled study. A placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect. The study population will consist of Asian treatment-naive genotype-1, chronic HCV-infected patients. The trial will involve a screening period at a maximum of 6 weeks before baseline, a 9-day treatment period (with 5 days of actual medication intake) and a 4-week follow-up period. Patients will be divided into 3 panels of 8 patients (Panel 1) or 5 patients (Panels 2 and 3). Treatment will be initiated in each panel of patients sequentially. In each panel, patients will receive JNJ-47910382 or placebo during 5 consecutive days. JNJ-47910382, or placebo, will be administered once daily. Treatments will be taken by mouth and with standardized meals in all dosing regimens. Patient safety will be monitored.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date April 21, 2014
Est. primary completion date April 21, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Documented chronic HCV infection (diagnosis of hepatitis C >= 6 months before the screening period)

- HCV geno- and subtype of 1a or 1b (Panel 1) or 1b (Panels 2 and 3)

- Patient has never received pegylated interferon, ribavirin, or any other approved or investigational antiviral treatment for chronic HCV infection

- Patient with HCV ribonucleic acid (RNA) level of >100,000 IU/mL at screening (as assessed by standard quantitative in vitro nucleic acid amplification assay)

- A Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 32.0 kg/m2, extremes included

- A body weight above 50 kg

- Normal 12-lead electrocardiogram (ECG) at screening

Exclusion Criteria:

- Evidence of or documented liver cirrhosis

- Evidence of decompensated liver disease

- Evidence of any other cause of significant liver disease in addition to hepatitis C

- History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in the Investigator's opinion would compromise patient's safety and/or compliance with the study procedures

- A positive urine drug (with exclusion of methadone or equivalent) test at study screening

- Patient with protocol-defined laboratory abnormalities at screening

- Patient coinfected with HIV-1 or HIV-2, or hepatitis A or B virus infection, or active tuberculosis at study screening

- Patient infected/coinfected with non-genotype 1 HCV at study screening

- Patient with any cardiac disease at screening, or any active clinically significant disease (eg, cardiac dysfunction, cardio(myo)pathy, cardiac insufficiency), or medical history or physical examination findings during screening that, in the Investigator's opinion, would compromise the outcome of the trial

- Patient having uncontrolled/unstable disease such as diabetes, epilepsy, a manifest psychiatric disease, or thyroid disease or disorders

- Patient with non-stable methadone (or equivalent drug) use

Study Design


Intervention

Drug:
JNJ-47910382 30 mg
JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
JNJ-47910382 90 mg
JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
JNJ-47910382 200 mg
JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
Placebo
Matching Placebo administered once daily as monotherapy for 5 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen R&D Ireland

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in HCV RNA levels over time during the 5-day treatment regimen Up to 4 weeks after the last dose of study medication.
Primary Number of participants with HCV RNA levels below the limit of detection Up to 4 weeks after the last dose of study medication.
Secondary Mean plasma concentrations of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary Maximum observed plasma concentration of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary Minimum observed plasma concentration of JNJ-47910382 Up to Day 9 of each treatment period
Secondary Time to reach the maximum plasma concentration of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary Area under the plasma concentration-time curve from time 0 to 24 hours of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary Average steady-state plasma concentration of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary Terminal elimination half life of JNJ-47910382 Up to Day 9 of each treatment period.
Secondary The number of participants affected by an adverse event Up to 30 days after the last dose of study medication
See also
  Status Clinical Trial Phase
Completed NCT02219503 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Phase 3
Completed NCT02216422 - A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection Phase 3
Completed NCT01700179 - Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants Phase 1
Completed NCT02486406 - A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Phase 2/Phase 3
Completed NCT01704755 - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Phase 3
Completed NCT01225380 - A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Phase 2
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Completed NCT02065999 - Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Completed NCT01715415 - A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults Phase 3
Completed NCT01716585 - A Study to Evaluate Chronic Hepatitis C Infection Phase 3
Completed NCT01453075 - Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) Phase 1
Completed NCT01011166 - Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) Phase 2
Completed NCT00557583 - Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults Phase 1
Recruiting NCT02583685 - Switching Regimen in Treating Cirrhotic HCV GT1b Subjects Phase 2
Recruiting NCT02578693 - Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Completed NCT02576314 - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients Phase 3
Not yet recruiting NCT01835938 - Clinical Investigation of Erlotinib as an HCV Entry Inhibitor Phase 1/Phase 2
Completed NCT01055821 - Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients Phase 2
Completed NCT01854697 - A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before Phase 3
Completed NCT01833533 - A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection Phase 3